Now that guidelines allow for the use of at least 5 years of endocrine therapeutics [24], and even 10 years for a subset of patients [25], it is not unlikely that such continuous and longitudinal ERα-inhibition would directly invoke a strong evolutionary pressure on the tumor. The gene discussed is ESR1; the disease is neoplasm.